Albireo - M&A Summary, Ownership, and Business Overview

Life ScienceCompany

Albireo M&A Summary

Albireo has acquired 1 company of its own.

Albireo has acquired in 1 US state. The Company’s most targeted sectors include life science (100%).

Albireo Ownership

Who owns Albireo?

Albireo is owned by Ipsen SA. It was acquired on January 9, 2023.

Was Albireo formerly PE-backed?

Yes. Albireo was formerly owned by 1 private investor.

Albireo Business Overview

Where is Albireo headquartered?

Albireo is headquartered in Boston, Massachusetts.

What is Albireo’s revenue?

Albireo disclosed revenue of 41M USD for 2021 and 8M USD for 2020.

What sector is Albireo in?

Albireo is a life science company.

When was Albireo founded?

Albireo was founded in 2008.

M&A Summary

  • M&A Total Activity1
    • M&A Buy Activity1
  • Total Sectors Invested 1
  • Total Countries Invested 1

Albireo

Albireo Pharma, Inc.

10 Post Office Square, Suite 1000,
Boston, Massachusetts 02109
United States,
(857) 254-5555
www.albireopharma.com

Albireo is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and in Europe for the treatment of PFIC. Bylvay is also being developed to treat other rare pediatric cholestatic liver diseases with a completed Phase III trial in ALGS, an ongoing Phase III study in biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. The company has also completed a Phase I clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden.


M&A Summary

Buy vs Sell

Year ≤ '19 '20 '21 '22 '23 '24 T
Buy (0.0/yr) # 1 - - - - - 1
Sell (0.0/yr) # - - - - - - 0
  1

Most Recent M&A

Company Date Value Type
Biodel, Inc. 2016-05-24 - Merger
Danbury, Connecticut · www.biodel.com
View All >>

M&A by Sector

Sector Buy # Value Sell # Value
Life Science 1 (100%) - - -
Total 1 - - -

By Geo

State/Country Buy Value Sell Value
United States 1 - - -
  Connecticut 1 - - -
Total 1 - - -

 Subscribe to unlock this and 208,055
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 201K M&A Transactions
  • 203K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.